SENATE BILL REPORT

SB 6013

As of January 13, 2014

Title: An act relating to making a technical correction to school law governing the use of epinephrine autoinjectors.

Brief Description: Making a technical correction to school law governing the use of epinephrine autoinjectors (EPI pens).

Sponsors: Senator Mullet.

Brief History:

Committee Activity: Early Learning & K-12 Education:

Staff: Katherine Taylor (786-7434)

Background: An epinephrine autoinjector is a medical device used to deliver a measured dose of epinephrine, also known as adrenaline, using autoinjector technology, most frequently for the treatment of acute allergic reactions to avoid or treat the onset of anaphylactic shock.

An autoinjector is a medical device designed to deliver a single dose of a particular, typically life-saving, drug. Most autoinjectors are spring-loaded syringes.

Anaphylactic shock is a serious allergic reaction that is rapid in onset and may cause death. It typically causes a number of symptoms including an itchy rash, throat swelling, and low blood pressure. Common causes include insect bites or stings, foods, and medications.

Trade names for an epinephrine autoinjector device include EpiPen, Twinject, Adrenaclick, Anapen, Jext, Allerject, and Auvi-Q.

Engrossed Senate Bill 5104, which involves placing epinephrine autoinjectors in schools, was passed by both houses during the 2013 legislative session and signed into law. The law went into effect July 28, 2013.

Summary of Bill: A technical correction is made to the statute that was most recently amended during the 2013 legislative session through Engrossed Senate Bill 5104.

Appropriation: None.

Fiscal Note: Not requested.

Committee/Commission/Task Force Created: No.

Effective Date: Ninety days after adjournment of session in which bill is passed.